Novo Nordisk is developing a promising obesity drug that may outperform existing options. Results of a clinical trial are anticipated in December, potentially boosting Novo's shares.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Novo Nordisk Stock Has Been Slammed. How a New Weight-Loss Drug Could Boost Shares by 10%.
